Financial Assistance
Newsletter Sign-up
Need Appointment
Contact Us
About Us

Rush University
For Physicians
For Rush Employees
For Students
Bill Payment Center
Rotate
<< Previous | New Search | Return to Search Results | Next >>

Cynthia L. Comella, MD

Cynthia L. Comella, MD
Appointment Request

Or call
(888) 352-RUSH for help arranging an appointment.
Specialty:
  • Neurology
Board Certification:
  • Neurology
Faculty Rank: Professor
Medical or Graduate Education: University of Cincinnati College of Medicine
Residency: Rush University Medical Center - Neurology
Fellowship: Rush University Medical Center - Movement Disorders; Sleep Medicine
Clinical Expertise:
  • Balance disorders
  • Blepharospasm
  • Botulinum toxin injections
  • Cervical dystonia
  • Chorea
  • Corticobasal degeneration
  • Dementia and degenerative disease
  • Dystonia
  • Hemifacial spasm
  • Movement disorders
  • Movement disorders, fragile X-associated
  • Multiple system atrophy
  • Myoclonus
  • Parkinsonism
  • Parkinson's disease
  • Progressive supranuclear palsy
  • Restless leg syndrome
  • Spasmodic dysphonia
  • Stiff-person syndrome
  • Tardive dyskinesia
  • Tics
  • Tremor
  • Writer's cramp
Research Interests:
  • Dystonia: clinical features and genetics
  • Restless leg syndrome: clinical research
  • Parkinson's disease
  • Neuropsychiatric features and genetics of Parkinson's disease
  • Women's health issues and Parkinson's disease
  • Clinical trials in Parkinson's disease
  • Genetics and movement disorders
  • Pharmacological studies of movement disorders
  • Occupational dystonias
  • Clinical trials in dystonia
Google Map
  • University Neurologists
  • Professional Building
  • 1725 W. Harrison St.
  • Suite 755
  • Chicago, IL  60612
  • Phone: (312) 563-2900
  • Fax: (312) 563-2024
  • View Larger MapDriving Directions

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.
    Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K.
    Lancet Neurol. 2013
    2013 May 30. doi:pii: S1474-4422(13)70117-0. 10.1016/S1474-4422(13)70117-0. [Epub ahead of print]
  2. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor.
    Prodoehl J, Li H, Planetta PJ, Goetz CG, Shannon KM, Tangonan R, Comella CL, Simuni T, Zhou XJ, Leurgans S, Corcos DM, Vaillancourt DE.
    Mov Disord. 2013
    2013 May 14. doi: 10.1002/mds.25491. [Epub ahead of print]
  3. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease.
    Corcos DM, Robichaud JA, David FJ, Leurgans SE, Vaillancourt DE, Poon C, Rafferty MR, Kohrt WM, Comella CL.
    Mov Disord. 2013
    2013 Mar 27. doi: 10.1002/mds.25380. [Epub ahead of print]
  4. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.
    Evidente VG, Fernandez HH, Ledoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL.
    J Neural Transm. 2013
    2013 Jun 19. [Epub ahead of print]
  5. Dystonia rating scales: Critique and recommendations.
    Albanese A, Sorbo FD, Comella C, Jinnah HA, Mink JW, Post B, Vidailhet M, Volkmann J, Warner TT, Leentjens AF, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A
    Mov. Disord.
    2013 Jun 15
    28(7):874-83.
  6. The focal dystonias: Current views and challenges for future research.
    Jinnah HA, Berardelli A, Comella C, Defazio G, Delong MR, Factor S, Galpern WR, Hallett M, Ludlow CL, Perlmutter JS, Rosen AR,
    Mov. Disord.
    2013 Jun 15
    28(7):926-43.
  7. Diffusion, spread, and migration of botulinum toxin.
    Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z
    Mov. Disord.
    2013 Jul 18
    :.
  8. Differences in brain activation between tremor- and nontremor-dominant Parkinson disease.
    Prodoehl J, Planetta PJ, Kurani AS, Comella CL, Corcos DM, Vaillancourt DE.
    JAMA Neurol. 2013
    2013 Jan 1
    70(1):100-6. doi: 10.1001/jamaneurol.2013.582.
  9. Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia.
    Fernandez HH, Pappert EJ, Comella CL, Evidente VG, Truong DD, Verma A, Jankovic J.
    Tremor Other Hyperkinet Mov (N Y). 2013
    2013 Apr 18
    3. doi:pii: tre-03-140-2921-1. Print 2013.
  10. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy.
    Neely KA, Planetta PJ, Prodoehl J, Corcos DM, Comella CL, Goetz CG, Shannon KL, Vaillancourt DE.
    PLoS One. 2013
    2013
    8(3):e58403. doi: 10.1371/journal.pone.0058403. Epub 2013 Mar 11.
  11. Differences in Brain Activation Between Tremor- and Nontremor-Dominant Parkinson Disease.
    Prodoehl J, Planetta PJ, Kurani AS, Comella CL, Corcos DM, Vaillancourt DE.
    Arch Neurol. 2012
    2012 Oct 8:1-7. doi: 10.1001/archneurol.2013.582. [Epub ahead of print]
  12. Reliability of a new scale for essential tremor.
    Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, Lewitt P, Lyons K, Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Watts R, Zesiewicz T.
    Mov Disord. 2012
    2012 Oct
    27(12):1567-9. doi: 10.1002/mds.25162. Epub 2012 Oct 2.
  13. Tai chi for patients with Parkinson's disease.
    Corcos DM, Comella CL, Goetz CG.
    N Engl J Med. 2012
    2012 May 3
    366(18):1737-8; author reply 1738. doi: 10.1056/NEJMc1202921#SA2. No abstract available.
  14. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
    Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S. XEOMIN Cervical Dystonia Study Group.
    J Neurol Sci.
    2011 Sep 15
    308(1-2):103-9
  15. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).
    Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, Sutch SM, Brin MF, Papapetropoulos S.
    BMC Neurol.
    2011 Nov 4
    11:140.
  16. Pre-operative evaluations for DBS in dystonia.
    Thobois S, Taira T, Comella C, Moro E, Bressman S, Albanese A.
    Mov Disord.
    2011 Jun
    26 Suppl 1:S17-22. doi: 10.1002/mds.23481.
  17. Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study
    Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Cote LJ, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Siderowf AD, Ross BM, Verbitsky M, Kisselev S, Ottman R, Clark LN, Marder KS
    J Int Neuropsychol Soc
    2011 Jan
    17(1):91-100
  18. Dystonias of the head and neck: An overview
    Charous SJ, Comella C
    Ear Nose Throat J
    2011 Feb
    90(2):E4-8
  19. Jaw-opening dystonia: Quality of life after botulinum toxin injections
    Charous SJ, Comella CL, Fan W
    Ear Nose Throat J
    2011 Feb
    90(2):E9-E12
  20. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-A randomized trial.
    Jankovic J, Comella C, Hanschmann A, Grafe S.
    Mov Disord.
    2011 Apr 22
    doi: 10.1002/mds.23658
  21. Early-onset primary dystonia.
    Robottom BJ, Weiner WJ, Comella CL.
    Handb Clin Neurol.
    2011
    100:465-79
  22. Sleep disorders in Parkinson's disease
    Videnovic A, Comella CL
    Handb Clin Neurol
    2011
    99:997-1010
  23. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study
    Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance MA, Bressman SB, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Marder K, Clark LN
    Arch Neurol
    2010 Sep
    67(9):1116-22
  24. Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease
    Prodoehl J, Spraker M, Corcos D, Comella C, Vaillancourt D
    Mov Disord
    2010 Oct 15
    25(13):2035-43
  25. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study
    Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN
    Arch Neurol
    2010 Jun
    67(6):731-8
  26. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations
    Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, Goetz CG
    Mov Disord
    2010 Dec 15
    25(16):2704-16
  27. Olfaction in Parkin heterozygotes and compound heterozygotes: The CORE-PD study
    Alcalay RN, Siderowf A, Ottman R, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Louis E, Ruiz D, Waters C, Fahn S, Cote L, Frucht S, Ford B, Orbe-Reilly M, Ross B, Verbitsky M, Kisselev S, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Rezak M, Novak KE, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Clark LN, Marder K
    Neurology
    2010 Dec 29
  28. Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease
    Spraker MB, Prodoehl J, Corcos DM, Comella CL, Vaillancourt DE
    Hum Brain Mapp
    2010 Dec
    31(12):1928-41.
  29. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo
    Menza M, Dobkin RD, Marin H, Gara M, Bienfait K, Dicke A, Comella CL, Cantor C, Hyer L
    Mov Disord
    2010 Aug 15
    25(11):1708-14
  30. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study
    Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K
    Mov Disord
    2010 Aug 15
    25(11):1627-32
  31. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease
    Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E
    J Clin Exp Neuropsychol
    2010 Aug
    32(7):775-9
  32. Treatment of focal dystonias with botulinum neurotoxin
    Hallett M, Benecke R, Blitzer A, Comella CL
    Toxicon
    2009 Oct
    54(5):628-33
  33. Variability of EMG patterns: a potential neurophysiological marker of Parkinson's disease?
    Robichaud JA, Pfann KD, Leurgans S, Vaillancourt DE, Comella CL, Corcos DM
    Clin Neurophysiol
    2009 Feb
    120(2):390-7
  34. Stimulation-induced parkinsonism after posteroventral deep brain stimulation of the globus pallidus internus for craniocervical dystonia
    Zauber SE, Watson N, Comella CL, Bakay RA, Metman LV
    J Neurosurg
    2009 Feb
    110(2):229-33
  35. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease
    Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS
    Arch Neurol
    2009 Dec
    66(12):1517-22
  36. Treatment of early Parkinson's disease. Part 2
    Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D
    Eur Neurol
    2009
    61(4):206-15
  37. Treatment of early Parkinson's disease. Part 1
    Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D
    Eur Neurol
    2009
    61(4):193-205
  38. Sleep disorders in Parkinson's disease
    Comella CL
    Curr Treat Options Neurol
    2008 May
    10(3):215-21
  39. Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment
    Weintraub D, Comella CL, Horn S
    Am J Manag Care
    2008 Mar
    14(2 Suppl):S40-8
  40. Parkinson's disease--Part 2: Treatment of motor symptoms
    Weintraub D, Comella CL, Horn S
    Am J Manag Care
    2008 Mar
    14(2 Suppl):S49-58
  41. Parkinson's disease--Part 3: Neuropsychiatric symptoms
    Weintraub D, Comella CL, Horn S
    Am J Manag Care
    2008 Mar
    14(2 Suppl):S59-69
  42. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
    Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group
    Mov Disord
    2008 Jul 30
    23(10):1353-60
  43. Changes in the relationship between movement velocity and movement distance in primary focal hand dystonia
    Prodoehl J, Corcos DM, Leurgans S, Comella CL, Weis-McNulty A, MacKinnon CD
    J Mot Behav
    2008 Jul
    40(4):301-13
  44. The treatment of cervical dystonia with botulinum toxins
    Comella CL
    J Neural Transm
    2008
    115(4):579-83
  45. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial
    Truong D, Comella C, Fernandez HH, Ondo WG; Dysport Benign Essential Blepharospasm Study Group
    Parkinsonism Relat Disord
    2008
    14(5):407-14
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript

Find a Doctor | Patient & Visitor Services | Health Information | Clinical Services | Events & Classes | News Room | Clinical Trials | Research at Rush
Nursing at Rush | Work at Rush | Giving to Rush | Directions to Rush | Disclaimer | Privacy Statement
For Physicians | For Rush Employees | For Students | Bill Payment Center | Site Map
© Rush University Medical Center
1653 W. Congress Parkway, Chicago, Illinois 60612